Torrens I

Language: English
References: 5
Page: 1511-1512
PDF size: 195.45 Kb.

ABSTRACT

The Congress of the European Society of Medical Oncology was celebrated on September 26 to 30, 2014, in the Fairground Institution of Madrid (IFEMA). In that meeting, the new scientific advances on cancer studies were presented. Advances in clinical trials of several aggressive cancer types were presented, including the Cleopatra clinical trial phase III in HER2 positive breast cancer. Detailed practices, policies and financial aspects relevant for the advancement of the collaboration between clinical researchers and healthcare personnel were also discussed. The need to provide an optimal care to cancer patients was debated as well.

REFERENCES

1. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. CLEOPATRA Study Group. N Engl J Med. 2012;366(2):109-19.

2. Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial firstline bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(12):1351-60.

3. Venook A, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O-Neil B, et al. Abstract 501O - CALGB/SWOG 80405: PHASE III trial of Irinotecan/5-FU/leucovorin (FOLFIRI) or Oxaliplatin/5-FU/ Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). 2014 [cited 2014 July 16]. Available from: http://www. esmo.org/Conferences/Past-Conferences/ ESMO-2014-Congress/News-Articles/ Results-From-the-CALGB-SWOG-80405- and-FIRE-3-AIO-KRK-0306-Studies-In-AllRAS-Wild-Type-Population

4. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-76.

5. National Cancer Institute. 2014 [cited 2014 July 16]. Available from: www. cancer.gov